Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of “Moderate Buy” from Analysts

Disc Medicine, Inc. (NASDAQ:IRON) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $105.80.

A number of brokerages have weighed in on IRON. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Morgan Stanley lifted their price target on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday. Truist Financial dropped their price target on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, Wedbush reiterated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th.

Disc Medicine Price Performance

Shares of IRON stock opened at $70.21 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The firm’s 50-day moving average is $68.44 and its two-hundred day moving average is $71.93. Disc Medicine has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a market capitalization of $2.68 billion, a PE ratio of -10.61 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Analysts predict that Disc Medicine will post -6.74 earnings per share for the current year.

Insider Transactions at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 5,731 shares of Disc Medicine stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $66.38, for a total transaction of $380,423.78. Following the completion of the sale, the insider directly owned 79,480 shares in the company, valued at $5,275,882.40. This trade represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jean M. Franchi sold 6,257 shares of Disc Medicine stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the completion of the transaction, the chief financial officer owned 64,333 shares of the company’s stock, valued at $4,454,416.92. This trade represents a 8.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 12,388 shares of company stock valued at $841,258. Company insiders own 3.76% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd acquired a new position in shares of Disc Medicine in the fourth quarter valued at approximately $33,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Disc Medicine in the third quarter valued at approximately $38,000. KBC Group NV acquired a new position in shares of Disc Medicine in the fourth quarter valued at approximately $80,000. Persistent Asset Partners Ltd acquired a new position in shares of Disc Medicine in the fourth quarter valued at approximately $141,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Disc Medicine by 36.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after purchasing an additional 490 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.